Arca
Skip to content
Tools
Tools

Subarachnoid hemorrhage

Drug research and approvals for subarachnoid hemorrhage: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 85 studies of subarachnoid hemorrhage are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 16 open orphan designations naming it.

  • Recruiting worldwide: 85
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 85 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 11

Phase 2 12 of 17

Phase 1 or earlier 5

How its trials ended

466 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 89 whose ending is known, 22% met their primary endpoint, 13% missed it and 64% stopped early.

  • Completed, result not reported16235%
  • Ongoing12126%
  • Status unknown9420%
  • Stopped: other or unclear296%
  • Met its primary endpoint204%
  • Stopped: enrollment or feasibility194%
  • Missed its primary endpoint123%
  • Stopped: lack of efficacy72%
  • Stopped: sponsor or business decision1<1%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jun 25, 2024Safety and tolerability of GTX-104 (nimodipine injection for iv infusion) compared with oral nimodipine in patients hospitalized for aneurysmal subarachnoid…Nimodipine (GTX-104)Grace TherapeuticsPending
Aug 21, 2018A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, phase 3 study to assess the efficacy and safety of clazosentan in…ClazosentanIdorsia Pharmaceuticals LtdOngoing
Aug 8, 2016Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study comparing EG-1962 to standard of care oral…Nimovent (EG-1962)Edge Therapeutics IncOngoing
May 1, 2015A pilot study of sub-anesthetic ketamine infusion for neuroprotection after aneurysmal subarachnoid hemorrhage: effects on white matter integrity, inflammatory…KetamineDr Andrew BakerClosed
Apr 16, 2014A phase 2, multicenter randomized, double-blind, placebo-controlled, safety and efficacy study evaluating a single dose of intravenous na 1 in patients with…NA-1Nono IncPending
Oct 9, 2013Ultra-early tranexamic acid after subarachnoid hemorrhageTranexamic acidSt Michaels HospitalPending
Jul 26, 2013Phase 1/2a multicenter, controlled, randomized, open-label, dose escalation, safety, tolerability, and pharmacokinetic study comparing EG-1962 and nimodipine…Nimovent (EG-1962)Edge Therapeutics IncClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 17
May 10, 2013NymalizeImprovement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid…Arbor Pharmaceuticals, Inc.Approved
Dec 26, 2024CeriopolymexTreatment of subarachnoid hemorrhageCenyx Biotech Inc.Designated
Aug 1, 2023Nimodipine intravenousTreatment of subarachnoid hemorrhageCipla Ltd.Designated
Oct 12, 2021Haptoglobin (Hp1-1), (Human)Treatment of subarachnoid hemorrhageCSL BehringDesignated
Nov 17, 2020(R)-6-(2-hydroxy-3-(4-(4-(trifluoromethyl)phenyl)piperazin-…Treatment of subarachnoid hemorrhageNeurOp Inc.Designated
Sep 9, 2020LumacaftorTreatment of subarachnoid hemorrhageQanatpharma AGDesignated
Sep 5, 2019FasudilTreatment of subarachnoid hemorrhageAneuryst, Inc.Designated
Mar 28, 2018MelatoninTreatment of subarachnoid hemorrhageWORPHMED SrlDesignated
Aug 10, 2017Nimodipine intravenousTreatment of subarachnoid hemorrhageGrace Therapeutics U.S., Inc.Designated
Aug 3, 20171,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadieneTreatment of subarachnoid hemorrhage (SAH)Edvince ABDesignated
Aug 22, 2016Stabilized sulforaphaneTreatment of subarachnoid hemorrhageEvgen Pharma PLCDesignated
Feb 8, 2016GlyburideTreatment of acute subarachnoid hemorrhageRemedy Pharmaceuticals, Inc.Designated
May 28, 2015Intraventricular nimodipineTreatment of subarachnoid hemorrhageEdge Therapeutics, Inc.Designated
May 14, 2013H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-…Treatment of subarachnoid hemorrhageNoNO, Inc.Designated
Jan 17, 2007Sodium nitritePrevention of vasospasm associated with subarachnoid hemorrhageHope PharmaceuticalsDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.